AI assistant
GlaxoSmithKline PLC Director's Dealing 2021
5262_dirs_2021-02-15_97a1c794-96b6-4de3-a1bd-7cea7c79522d.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 0990P
GlaxoSmithKline PLC
15 February 2021
GlaxoSmithKline plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in 2018 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions. Awards were made in 2018 and the three-year performance period commenced on 1 January 2018 and ended on 31 December 2020. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.
The performance measure vesting details for those PDMRs who received awards in 2018 are set out in the following table.
| Outcome and Vesting Level | |||
| Portion of the Award | Measure and Outcome | % of maximum | % of award |
| 1/3rd | Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £15.64bn, which is above the level of £12.60bn required for maximum vesting. Adjustments to the original target and vesting schedule were communicated in the 2019 Annual Report. |
100 | 33.333 |
| 1/3rd | Total Shareholder Return - For the three years ending 31 December 2020, the Company's Total Shareholder Return ranked 9th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK. | 0 | 0 |
| 1/3rd | R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £7.337bn, which is above the level of £4.387bn required for maximum vesting. The threshold vesting level was £3.589bn. | 100 | 33.333 |
| Total vesting for 2018 award Lapsed |
66.666% 33.334% |
The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 11 February 2021. The balance of the award made to each PDMR and PCA has lapsed.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on the vesting date were £12.552 and $35.52.
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms E Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 340,753 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr H Barron | |||
| b) | Position/status | Chief Scientific Officer and President, R&D | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The number of ADSs vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 180,833 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr R Connor | |||
| b) | Position/status | President, Global Vaccines | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 135,107 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms D Conrad | |||
| b) | Position/status | SVP, Human Resources | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 9,181 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr J Ford | |||
| b) | Position/status | SVP & General Counsel | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The number of ADSs vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 5,229 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr N Hirons | |||
| b) | Position/status | SVP, Global Ethics and Compliance | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 50,108 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms S Jackson | |||
| b) | Position/status | SVP, Global Communications & CEO Office | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 9,181 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr D Jackson | |||
| b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications & CEO Office) | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 4,335 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr B McNamara | |||
| b) | Position/status | CEO, GSK Consumer Healthcare | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The number of ADSs vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 84,162 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr L Miels | |||
| b) | Position/status | President, Global Pharmaceuticals | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 175,482 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr D Redfern | |||
| b) | Position/status | Chief Strategy Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 92,622 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr R Simard | |||
| b) | Position/status | President, Pharmaceuticals Supply Chain | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 9,181 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms K Terrell | |||
| b) | Position/status | Chief Digital & Technology Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The number of ADSs vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 69,781 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr P Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 66,043 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms D Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 12,589 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms V Whyte | |||
| b) | Position/status | Company Secretary | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The number of Ordinary Shares vesting on awards granted in 2018 under the Company's 2017 Performance Share Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 9,181 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-02-11 | |||
| f) | Place of the transaction | N/A |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBELFFFLLBBBK